Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147583 | 0.88 | ALOX15 (0.68) | ALOX15RXFP1NPC1RAB9AAR | |
| SCHEMBL20494636 | 0.83 | FLT3 (0.49) | ALOX15ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL30071440 | 0.83 | FLT3 (0.49) | ALOX15ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL30071390 | 0.82 | KDM4E (0.61) | FLT3 | |
| SCHEMBL7493915 | 0.82 | KDM4E (0.61) | FLT3 | |
| SCHEMBL9051846 | 0.80 | AR (0.49) | ROCK2ROCK1ARFLT3 | |
| SCHEMBL2760015 | 0.79 | KDM4E (0.66) | ALOX15RXFP1NPC1RAB9AMEN1 | |
| SCHEMBL3642463 | 0.79 | ALOX15 (0.52) | ALOX15ROCK2ROCK1 | |
| SCHEMBL16571383 | 0.77 | ALOX15 (0.43) | ALOX15RXFP1NPC1RAB9AMEN1 | |
| SCHEMBL20494524 | 0.77 | ALOX15 (0.64) | ALOX15NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | ALOX15 1093/4885ROCK2 2016/4885ROCK1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.